Drugs / CT125A cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04767308 | Mar 2021 → Sep 2023 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +2 | Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT125A cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04767308 ↗ |
| Known as | CT125A | “This phase 1 trial evaluates autologous CD5-targeting CAR-T cells with CD5 gene deletion (CT125A) in seven patients with relapsed/refractory CD5+ hematologic malignancies.” PMID 41633358 ↗ Feb 2026 |
| Action | Deplete | “Post-infusion immunophenotyping shows persistent depletion of CD5+ T cells and CD19+ B cells” PMID 41633358 ↗ Feb 2026 |
| Modality | Cell therapy | “This phase 1 trial evaluates autologous CD5-targeting CAR-T cells with CD5 gene deletion (CT125A) in seven patients with relapsed/refractory CD5+ hematologic malignancies.” PMID 41633358 ↗ Feb 2026 |
| Route | Intravenous | “After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion.” NCT04767308 ↗ |
| Target | CD5 | “This phase 1 trial evaluates autologous CD5-targeting CAR-T cells with CD5 gene deletion (CT125A) in seven patients with relapsed/refractory CD5+ hematologic malignancies.” PMID 41633358 ↗ Feb 2026 |